The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) and Sana Biotechnology (NASDAQ:SANA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends. Valuation and Earnings This table compares Kyverna […]
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) and Sana Biotechnology (NASDAQ:SANA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Institutional & Insider Ownership 18.1% of Kyverna […]
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.28), Briefing.com reports. During the same quarter last year, the company posted ($12.10) earnings per share. Kyverna Therapeutics Stock Performance KYTX traded up […]